Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03151551




Registration number
NCT03151551
Ethics application status
Date submitted
4/05/2017
Date registered
12/05/2017

Titles & IDs
Public title
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
Scientific title
A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
Secondary ID [1] 0 0
I1F-MC-RHCF
Secondary ID [2] 0 0
16687
Universal Trial Number (UTN)
Trial acronym
SPIRIT-H2H
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psoriatic Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ixekizumab
Treatment: Drugs - Adalimumab

Experimental: Ixekizumab - 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants.

80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps.

80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps.

Active comparator: Adalimumab - 80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps.

40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps.


Treatment: Drugs: Ixekizumab
Administered SC

Treatment: Drugs: Adalimumab
Administered SC
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100)
Timepoint [1] 0 0
Week 24
Secondary outcome [1] 0 0
Percentage of Participants Achieving ACR50
Timepoint [1] 0 0
Week 24
Secondary outcome [2] 0 0
Percentage of Participants Achieving PASI100
Timepoint [2] 0 0
Week 24

Eligibility
Key inclusion criteria
* Presence of established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria
* Active PsA defined as the presence of at least 3 (out of 68) tender and at least 3 (out of 66) swollen joints
* Presence of active plaque psoriasis with a BSA =3%
* Men must agree to use a reliable method of birth control or remain abstinent during the study
* Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
* Have had an inadequate response when treated with 1 or more conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Current or prior use of biologic agents for treatment of Ps or PsA
* Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA
* Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab
* Serious disorder or illness other than psoriatic arthritis
* Serious infection within the last 3 months
* Active Crohn's disease or active ulcerative colitis
* Active vasculitis or uveitis
* Diagnosis of or history of malignant disease <5 years prior to randomization
* Women who are breastfeeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/08/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
4/09/2019
Sample size
Target
Accrual to date
Final
566
Recruitment in Australia
Recruitment state(s)
NSW,SA,TAS,VIC
Recruitment hospital [1] 0 0
Combined Rheumatology Practice (CRP) - Kogarah
Recruitment hospital [2] 0 0
Rheumatology, The Queen Elizabeth Hospital - Woodville South
Recruitment hospital [3] 0 0
Southern Clinical Research Pty Ltd - Hobart
Recruitment hospital [4] 0 0
Emeritus Research - Camberwell
Recruitment hospital [5] 0 0
St Vincents Hospital Melbourne - Fitzroy
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
5011 - Woodville South
Recruitment postcode(s) [3] 0 0
7000 - Hobart
Recruitment postcode(s) [4] 0 0
3124 - Camberwell
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Tucuman
Country [3] 0 0
Argentina
State/province [3] 0 0
Ciudad Autonoma de Buenos Aire
Country [4] 0 0
Argentina
State/province [4] 0 0
Cordoba
Country [5] 0 0
Argentina
State/province [5] 0 0
San Juan
Country [6] 0 0
Austria
State/province [6] 0 0
Wien
Country [7] 0 0
Belgium
State/province [7] 0 0
Genk
Country [8] 0 0
Belgium
State/province [8] 0 0
Gent
Country [9] 0 0
Belgium
State/province [9] 0 0
Gilly
Country [10] 0 0
Belgium
State/province [10] 0 0
Leuven
Country [11] 0 0
Belgium
State/province [11] 0 0
Mons
Country [12] 0 0
Canada
State/province [12] 0 0
Ontario
Country [13] 0 0
Canada
State/province [13] 0 0
Quebec
Country [14] 0 0
Canada
State/province [14] 0 0
Saskatchewan
Country [15] 0 0
Denmark
State/province [15] 0 0
Hovedstaden
Country [16] 0 0
Denmark
State/province [16] 0 0
Aalborg
Country [17] 0 0
Finland
State/province [17] 0 0
Helsinki
Country [18] 0 0
Finland
State/province [18] 0 0
Hyvinkaa
Country [19] 0 0
Finland
State/province [19] 0 0
Kouvola
Country [20] 0 0
Finland
State/province [20] 0 0
Turku
Country [21] 0 0
France
State/province [21] 0 0
Chambray-lès-Tours
Country [22] 0 0
France
State/province [22] 0 0
La Roche Sur Yon
Country [23] 0 0
France
State/province [23] 0 0
Lyon Cedex 03
Country [24] 0 0
France
State/province [24] 0 0
Montpellier Cedex 5
Country [25] 0 0
France
State/province [25] 0 0
Orleans CEDEX 2
Country [26] 0 0
France
State/province [26] 0 0
Toulouse cedex 9
Country [27] 0 0
Germany
State/province [27] 0 0
Bayern
Country [28] 0 0
Germany
State/province [28] 0 0
Hessen
Country [29] 0 0
Germany
State/province [29] 0 0
Nordrhein-Westfalen
Country [30] 0 0
Germany
State/province [30] 0 0
Hamburg
Country [31] 0 0
Hungary
State/province [31] 0 0
Jasz-Nagykun-Szolnok
Country [32] 0 0
Hungary
State/province [32] 0 0
Budapest
Country [33] 0 0
Hungary
State/province [33] 0 0
Veszprem
Country [34] 0 0
India
State/province [34] 0 0
Andhra Pradesh
Country [35] 0 0
India
State/province [35] 0 0
Delhi
Country [36] 0 0
India
State/province [36] 0 0
Gujarat
Country [37] 0 0
India
State/province [37] 0 0
Haryana
Country [38] 0 0
India
State/province [38] 0 0
Karnataka
Country [39] 0 0
India
State/province [39] 0 0
Maharashtra
Country [40] 0 0
India
State/province [40] 0 0
Telengana
Country [41] 0 0
India
State/province [41] 0 0
West Bengal
Country [42] 0 0
Israel
State/province [42] 0 0
Ashkelon
Country [43] 0 0
Israel
State/province [43] 0 0
Haifa
Country [44] 0 0
Israel
State/province [44] 0 0
Kfar Saba
Country [45] 0 0
Israel
State/province [45] 0 0
Petach Tikva
Country [46] 0 0
Israel
State/province [46] 0 0
Ramat Gan
Country [47] 0 0
Israel
State/province [47] 0 0
Tel Aviv
Country [48] 0 0
Israel
State/province [48] 0 0
Zerifin
Country [49] 0 0
Italy
State/province [49] 0 0
Milano
Country [50] 0 0
Italy
State/province [50] 0 0
Bologna
Country [51] 0 0
Italy
State/province [51] 0 0
Catania
Country [52] 0 0
Italy
State/province [52] 0 0
Chieti
Country [53] 0 0
Italy
State/province [53] 0 0
Roma
Country [54] 0 0
Italy
State/province [54] 0 0
Verona
Country [55] 0 0
Mexico
State/province [55] 0 0
Baja California
Country [56] 0 0
Mexico
State/province [56] 0 0
Coahuila
Country [57] 0 0
Mexico
State/province [57] 0 0
Distrito Federal
Country [58] 0 0
Mexico
State/province [58] 0 0
Michoacan
Country [59] 0 0
Mexico
State/province [59] 0 0
Sinaloa
Country [60] 0 0
Mexico
State/province [60] 0 0
Yucatán
Country [61] 0 0
Netherlands
State/province [61] 0 0
Sneek
Country [62] 0 0
Poland
State/province [62] 0 0
Elblag
Country [63] 0 0
Poland
State/province [63] 0 0
Lodz
Country [64] 0 0
Poland
State/province [64] 0 0
Nowa Sol
Country [65] 0 0
Poland
State/province [65] 0 0
Warsaw
Country [66] 0 0
Poland
State/province [66] 0 0
Wroclaw
Country [67] 0 0
South Africa
State/province [67] 0 0
Eastern Cape
Country [68] 0 0
South Africa
State/province [68] 0 0
Gauteng
Country [69] 0 0
South Africa
State/province [69] 0 0
KwaZulu-Natal
Country [70] 0 0
South Africa
State/province [70] 0 0
Western Cape
Country [71] 0 0
South Africa
State/province [71] 0 0
Durban
Country [72] 0 0
South Africa
State/province [72] 0 0
Muckleneuk
Country [73] 0 0
South Africa
State/province [73] 0 0
Pretoria
Country [74] 0 0
Spain
State/province [74] 0 0
Alicante
Country [75] 0 0
Spain
State/province [75] 0 0
La Coruna
Country [76] 0 0
Spain
State/province [76] 0 0
Barcelona
Country [77] 0 0
Spain
State/province [77] 0 0
Sevilla
Country [78] 0 0
Sweden
State/province [78] 0 0
Västmanland
Country [79] 0 0
Sweden
State/province [79] 0 0
Malmo
Country [80] 0 0
Sweden
State/province [80] 0 0
Stockholm
Country [81] 0 0
Switzerland
State/province [81] 0 0
Sankt Gallen
Country [82] 0 0
Switzerland
State/province [82] 0 0
Genève
Country [83] 0 0
Ukraine
State/province [83] 0 0
Kharkiv
Country [84] 0 0
Ukraine
State/province [84] 0 0
Kyiv
Country [85] 0 0
Ukraine
State/province [85] 0 0
Odesa
Country [86] 0 0
Ukraine
State/province [86] 0 0
Ternopil
Country [87] 0 0
Ukraine
State/province [87] 0 0
Vinnytsya
Country [88] 0 0
Ukraine
State/province [88] 0 0
Zaporizhzhia
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Cambridgeshire
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Cornwall
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Hants
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Manchester
Country [93] 0 0
United Kingdom
State/province [93] 0 0
North Lanarkshire
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Scotland
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Surrey
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Tyneside
Country [97] 0 0
United Kingdom
State/province [97] 0 0
West Midlands
Country [98] 0 0
United Kingdom
State/province [98] 0 0
West Yorkshire
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Wiltshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
When will data be available (start and end dates)?
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Available to whom?
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://vivli.org/


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT03151551